Targeting sphingolipid metabolism with the sphingosine kinase inhibitor SKI-II overcomes hypoxia-induced chemotherapy resistance in glioblastoma cells: effects on cell death, self-renewal, and invasion

[1]  B. Lutz,et al.  Lipidomics and Transcriptomics in Neurological Diseases. , 2022, Journal of visualized experiments : JoVE.

[2]  M. I. Hassan,et al.  Targeting the Sphingosine Kinase/Sphingosine-1-Phosphate Signaling Axis in Drug Discovery for Cancer Therapy , 2021, Cancers.

[3]  P. Limonta,et al.  Cancer Stem Cells—Key Players in Tumor Relapse , 2021, Cancers.

[4]  B. Lutz,et al.  Broad Lipidomic and Transcriptional Changes of Prophylactic PEA Administration in Adult Mice , 2019, Front. Neurosci..

[5]  B. Kaina,et al.  Are There Thresholds in Glioblastoma Cell Death Responses Triggered by Temozolomide? , 2019, International journal of molecular sciences.

[6]  Weiwei Ni,et al.  Sphingosine kinase inhibitors: A patent review. , 2018, International journal of molecular medicine.

[7]  Yusuf A. Hannun,et al.  Sphingolipids and their metabolism in physiology and disease , 2017, Nature Reviews Molecular Cell Biology.

[8]  Edward F. Chang,et al.  Tumor Evolution of Glioma-Intrinsic Gene Expression Subtypes Associates with Immunological Changes in the Microenvironment. , 2017, Cancer cell.

[9]  Wei Wu,et al.  Temozolomide induces autophagy in primary and established glioblastoma cells in an EGFR independent manner. , 2017, Oncology letters.

[10]  Yadira F. Ordóñez,et al.  Dihydroceramide desaturase inhibitors induce autophagy via dihydroceramide-dependent and independent mechanisms. , 2017, Biochimica et biophysica acta. General subjects.

[11]  H. Feng,et al.  Cancer stem-like cells can be induced through dedifferentiation under hypoxic conditions in glioma, hepatoma and lung cancer , 2017, Cell Death Discovery.

[12]  Christian Stüllein,et al.  A Novel Computer-Assisted Approach to evaluate Multicellular Tumor Spheroid Invasion Assay , 2016, Scientific Reports.

[13]  Voichita D. Marinescu,et al.  The Human Glioblastoma Cell Culture Resource: Validated Cell Models Representing All Molecular Subtypes , 2015, EBioMedicine.

[14]  S. Summers,et al.  Dihydroceramides: From Bit Players to Lead Actors* , 2015, The Journal of Biological Chemistry.

[15]  A. Kopp-Schneider,et al.  A sphingosine kinase inhibitor combined with temozolomide induces glioblastoma cell death through accumulation of dihydrosphingosine and dihydroceramide, endoplasmic reticulum stress and autophagy , 2014, Cell Death and Disease.

[16]  Atique U. Ahmed,et al.  Conversion of differentiated cancer cells into cancer stem-like cells in a glioblastoma model after primary chemotherapy , 2014, Cell Death and Differentiation.

[17]  K. McDonald,et al.  A Metabolic Shift Favoring Sphingosine 1-Phosphate at the Expense of Ceramide Controls Glioblastoma Angiogenesis* , 2013, The Journal of Biological Chemistry.

[18]  N. Waterhouse,et al.  Flow cytometry based assays for the measurement of apoptosis-associated mitochondrial membrane depolarisation and cytochrome c release. , 2013, Methods.

[19]  David R McIlwain,et al.  Caspase functions in cell death and disease. , 2013, Cold Spring Harbor perspectives in biology.

[20]  L. Pardo,et al.  Human Glioma–Initiating Cells Show a Distinct Immature Phenotype Resembling but Not Identical to NG2 Glia , 2013, Journal of neuropathology and experimental neurology.

[21]  Y. Peterson,et al.  Characterization of Isoenzyme-Selective Inhibitors of Human Sphingosine Kinases , 2012, PloS one.

[22]  Sangeeta Khare,et al.  Guidelines for the use and interpretation of assays formonitoring autophagy (3rd edition) , 2016 .

[23]  Robert Clarke,et al.  Guidelines for the use and interpretation of assays for monitoring autophagy , 2012 .

[24]  L. Obeid,et al.  Still benched on its way to the bedside: sphingosine kinase 1 as an emerging target in cancer chemotherapy , 2011, Critical reviews in biochemistry and molecular biology.

[25]  G. Arismendi-Morillo,et al.  Electron microscopy morphology of the mitochondrial network in gliomas and their vascular microenvironment. , 2011, Biochimica et biophysica acta.

[26]  D. Salvemini,et al.  Role for peroxynitrite in sphingosine-1-phosphate-induced hyperalgesia in rats , 2011, PAIN®.

[27]  M. Cabot,et al.  Inhibition of NADPH oxidase by glucosylceramide confers chemoresistance , 2010, Cancer biology & therapy.

[28]  S. Leenstra,et al.  Absence of the MGMT protein as well as methylation of the MGMT promoter predict the sensitivity for temozolomide , 2010, British Journal of Cancer.

[29]  S. Gabriel,et al.  Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. , 2010, Cancer cell.

[30]  T. Chou.  Drug combination studies and their synergy quantification using the Chou-Talalay method. , 2010, Cancer research.

[31]  Y. Hannun,et al.  Antiapoptotic roles of ceramide‐synthase‐6‐generated C16‐ceramide via selective regulation of the ATF6/ CHOP arm of ER‐stress‐response pathways , 2010, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[32]  João Wosniak,et al.  Mechanisms and implications of reactive oxygen species generation during the unfolded protein response: roles of endoplasmic reticulum oxidoreductases, mitochondrial electron transport, and NADPH oxidase. , 2009, Antioxidants & redox signaling.

[33]  G. Smyth,et al.  ELDA: extreme limiting dilution analysis for comparing depleted and enriched populations in stem cell and other assays. , 2009, Journal of immunological methods.

[34]  R. Mirimanoff,et al.  Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. , 2009, The Lancet. Oncology.

[35]  S. Milstien,et al.  Apoptosis induces expression of sphingosine kinase 1 to release sphingosine‐1‐phosphate as a “come‐and‐get‐me” signal , 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[36]  Ting-Chao Chou,et al.  Preclinical versus clinical drug combination studies , 2008, Leukemia & lymphoma.

[37]  J. Rommelaere,et al.  Cytosolic Activation of Cathepsins Mediates Parvovirus H-1-Induced Killing of Cisplatin and TRAIL-Resistant Glioma Cells , 2007, Journal of Virology.

[38]  Y. Zhuang,et al.  Antitumor Activity of Sphingosine Kinase Inhibitors , 2006, Journal of Pharmacology and Experimental Therapeutics.

[39]  Kanyawim Kirtikara,et al.  Sulforhodamine B colorimetric assay for cytotoxicity screening , 2006, Nature Protocols.

[40]  A. Unterberg,et al.  Different angiogenic phenotypes in primary and secondary glioblastomas , 2006, International journal of cancer.

[41]  M. Weller,et al.  O6‐methylguanine DNA methyltransferase and p53 status predict temozolomide sensitivity in human malignant glioma cells , 2006, Journal of neurochemistry.

[42]  R. Austin,et al.  Peroxynitrite Causes Endoplasmic Reticulum Stress and Apoptosis in Human Vascular Endothelium: Implications in Atherogenesis , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[43]  Martin J. van den Bent,et al.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.

[44]  R. Stupp,et al.  Plasma and Cerebrospinal Fluid Population Pharmacokinetics of Temozolomide in Malignant Glioma Patients , 2004, Clinical Cancer Research.

[45]  Daniel J Brat,et al.  Pseudopalisades in Glioblastoma Are Hypoxic, Express Extracellular Matrix Proteases, and Are Formed by an Actively Migrating Cell Population , 2004, Cancer Research.

[46]  J. García-Sancho,et al.  Calcium Influx through Receptor-operated Channel Induces Mitochondria-triggered Paraptotic Cell Death* 210 , 2003, The Journal of Biological Chemistry.

[47]  Pin-Lan Li,et al.  Ceramide-induced activation of NADPH oxidase and endothelial dysfunction in small coronary arteries. , 2003, American journal of physiology. Heart and circulatory physiology.

[48]  L. Genestier,et al.  Caspase-Independent Phosphatidylserine Exposure During Apoptosis of Primary T Lymphocytes1 , 2002, The Journal of Immunology.

[49]  D. Bredesen,et al.  An alternative, nonapoptotic form of programmed cell death. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[50]  K. Scotto,et al.  Ceramide synthase mediates daunorubicin-induced apoptosis: An alternative mechanism for generating death signals , 1995, Cell.

[51]  M. Stevens,et al.  NMR and molecular modeling investigation of the mechanism of activation of the antitumor drug temozolomide and its interaction with DNA. , 1994, Biochemistry.

[52]  Y. Hannun,et al.  Programmed cell death induced by ceramide. , 1993, Science.

[53]  S. Spiegel,et al.  Sphingosine-1-phosphate, a novel lipid, involved in cellular proliferation , 1991, The Journal of cell biology.

[54]  G. Margison,et al.  Reduction of the toxicity and mutagenicity of alkylating agents in mammalian cells harboring the Escherichia coli alkyltransferase gene. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[55]  Michael Weller,et al.  Standards of care for treatment of recurrent glioblastoma--are we there yet? , 2013, Neuro-oncology.

[56]  F. Turkheimer,et al.  A new model for prediction of drug distribution in tumor and normal tissues: pharmacokinetics of temozolomide in glioma patients. , 2009, Cancer research.

[57]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[58]  T. Chou,et al.  Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. , 1984, Advances in enzyme regulation.